Belgium· BE-AMP-SAM207602-00
Roferon-A 3 10*6 IU
A interferon alfa-2a product containing interferon alfa-2a, registered in Belgium by Roche. The same ATC class is registered in 4 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Interferon alfa-2a is registered in 4 of 19 countries.
Countries holding a registration under ATC L03AB04 (interferon alfa-2a), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 3 of them publish a price we can compare per daily dose
Interferon alfa-2a · ATC L03AB04
4 / 19 countries
- Belgiumprice
- Finlandprice
- Spainprice
- United Kingdom
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Interferon Alfa-2a
- Manufacturer
- Roche
- Country
- Belgium (BE)
- ATC code
- L03AB04
- ATC class
- Interferon alfa-2a
- Defined daily dose
- 2 MIO, E
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb0298380
- be_apb0732453
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
235 interactions on record for interferon alfa-2a.
Graded by severity as the source publishes them — 36 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Interferon alfa-2a · interactions on record
235 records
- 36 severe
- 197 moderate
- 2 minor
Most severe, free to view
- EltrombopagB02BX05severe
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- ZidovudineJ05AF01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Interferon alfa-2a in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/473240dd-6b26-4a09-b457-5d2d2ce71b24 GET /v1/drugs/473240dd-6b26-4a09-b457-5d2d2ce71b24?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled syringe",
"source": "afmps",
"status": "REVOKED",
"name_en": "Roferon-A 3 10*6 IU",
"name_fr": "Roferon-A 3 10*6 IU",
"name_nl": "Roferon-A 3 10*6 IU",
"amp_code": "SAM207602-00",
"strengths": [
"6000000.0000",
"6000000.0000"
],
"pack_count": 7,
"substances": [
"Interferon Alfa-2a"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Interferon Alfa-2a",
"authorisation_numbers": [
"BE207602"
]
}See everything about interferon alfa-2a.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.